Authors and Disclosures
Caroline Gordon1,2,3, Maame-Boatemaa Amissah-Arthur1, Mary Gayed1,3, Sue Brown4, Ian N. Bruce5,6, David D'Cruz7, Benjamin Empson8, Bridget Griffiths9, David Jayne10,11, Munther Khamashta12,13, Liz Lightstone14, Peter Norton15, Yvonne Norton15, Karen Schreiber13 and David Isenberg16 for the British Society for Rheumatology Standards, Audit and Guidelines Working Group
1Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, 2Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals NHS Trust, 3Rheumatology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, 4Royal National Hospital for Rheumatic Diseases, Bath, 5Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute for Inflammation and Repair, University of Manchester, Manchester Academic Health Sciences Centre, 6The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, 7Louise Coote Lupus Unit, Guy's Hospital, London, 8Laurie Pike Health Centre, Modality Partnership, Birmingham, 9Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne, 10Department of Medicine, University of Cambridge, 11Lupus and Vasculitis Unit, Addenbrooke's Hospital, Cambridge, 12Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, 13Division of Women's Health, King's College London, 14Section of Renal Medicine and Vascular Inflammation, Division of Immunology and Inflammation, Department of Medicine, Imperial College London, London, 15LUPUS UK, Romford, Essex and 16Centre for Rheumatology, University College London, London, UK
Correspondence to
Caroline Gordon, Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham Research Laboratories, New Queen Elizabeth Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, UK. E-mail: p.c.gordon@bham.ac.uk
Disclosure statement
D.D.'C. has undertaken consultancies and received honoraria from GlaxoSmithKline/Human Genome Sciences and Roche, has been a member of the speakers' bureau for GlaxoSmithKline/Human Genome Sciences, Union Chimique Belge (UCB) and Eli Lilly and has received research grant support from Aspreva/Vifor Pharma. C.G. has undertaken consultancies and received honoraria from Bristol-Myers Squibb, Eli-Lilly, GlaxoSmithKline, MedImmune, Merck Serono, Parexel, Roche and UCB, has been a member of the speakers' bureau for GlaxoSmithKline, UCB and Lilly and has received research grant support from Aspreva/Vifor Pharma in the past and UCB currently. Y.N. has received funding to attend scientific meetings and received honoraria from UCB and GlaxoSmithKline. P.N. has received funding to attend scientific meetings and received honoraria from UCB. I.N.B. has undertaken consultancies and received honoraria from AstraZeneca, GlaxoSmithKline, MedImmune, Merck Serono, Pfizer, Roche and UCB, has been a member of the speakers' bureau for GlaxoSmithKline, UCB and Pfizer and has received research grant income from Genzyme Sanofi, GlaxoSmithKline, UCB and Roche. B.G. has received honoraria from Pfizer. M.K. has received funding to attend scientific meetings and honoraria from AstraZeneca, MedImmune, GlaxoSmithKline, INOVA Diagnostics and UCB. S.B. has received honoraria from Actelion INB to attend scientific meetings, has undertaken consultancies and received honoraria from AstraZeneca, GlaxoSmithKline, MedImmune, Merck Serono, Pfizer, Roche and UCB and has been a member of the speakers' bureau for GlaxoSmithKline, UCB and Pfizer. M.G. has received funding to support scientific meetings from Roche, Abbvie and Bristol-Myers Squibb. D.J. has received research grants, honoraria and consulting fees from Roche/Genentech, consulting fees from Boehringer Ingelheim, Chemocentryx, GlaxoSmithKline and Medimmune and is a Board member of Aurinia Pharmaceuticals. D.I. has consulted for Merck Serono, Eli Lilly, Celegene, UCB, XTLBio, Anthera and Baxalta; the honoraria received have been passed on to a local arthritis charity. L.L. has received research funding in grants/in kind from Roche and Genentech, has acted as an advisor to Genentech, Medimmune and Rigel and has received honoraria/travel grants from Genentech, Roche and UCB. K.S. received funding to attend a scientific meeting from Daiichi Sankyo. All other authors have declared no conflicts of interest.
Comments